View Full Version : Interim results of a multiple ascending dose study of R1626 (Hepatitis C)

05-04-2006, 11:45 PM
Reported by Jules Levin
EASL conference
April 29, 2006, Vienna, Austria

Stuart Roberts (The Alfred Hospital & Centre for Clinical Studies, Melbourne, Australia) reported these study results. One of the big stories here at EASL is whether or not Vertex or Schering will use ritonavir to boost their HCV PI. Abbott reported intriguing data here showing in rat & human microsomes that ritonavir can significantly boost the drug levels for both HCV protease inhibitors VX-950 & SCH 503034, as it does for HIV protease inhibitors. But it remains to be seen whether Vertex & Schering will utilize this boosting approach. Boosting with ritonavir can make the HCV PI regimens more convenient by reducing the dose of the HCV PI and reducing the daily dosing regimens as both HCV PIs are dosed now 3 times per day.


R1626, a novel nucleoside analogue HCV polymerase inhibitor, is well tolerated and shows promising antiviral activity.

Additional high dose groups are ongoing.

Phase II combination therapy clinical trial planned to start in Q3 2006.